Joachim Tillner
Frankfurt Am Main, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial.
Journal: Obesity (Silver Spring, Md.)
Published: June 29, 2022
Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 27, 2021
A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity.
Journal: Journal of the Endocrine Society
Published: March 11, 2021
Prolonged Glucagon Infusion Does Not Affect Energy Expenditure in Individuals with Overweight/Obesity: A Randomized Trial.
Journal: Obesity (Silver Spring, Md.)
Published: September 23, 2020
Automated GMP-Compliant Production of [68Ga]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 29, 2020
Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 01, 2020
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Journal: Diabetes, obesity & metabolism
Published: February 07, 2018
Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects.
Journal: Clinical pharmacology in drug development
Published: November 25, 2014
Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
Journal: Diabetes, obesity & metabolism
Published: July 31, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026